FDA Warning Letters · October 20, 2026 · Primary source
Baxter International Inc.
Summary
FDA's Center for Drug Evaluation and Research issued a warning letter dated September 29, 2026, to Baxter International Inc. concerning its Round Lake, Illinois injectable drug manufacturing facility, inspected March 23 through April 2, 2026. The letter identifies CGMP violations under 21 CFR 211.42(c) and 211.113(b), specifically recurring cephalosporin cross-contamination of non-beta-lactam drug products detected since January 2025, inadequate environmental monitoring, and inadequate aseptic processing controls. FDA found Baxter's post-inspection response inadequate and directed comprehensive independent risk assessments, remediation plans, and enhanced contamination controls.
What this may mean
Baxter faces potential seizure, injunction, and recall liability for injectable drug products manufactured at the Round Lake facility if cross-contamination issues are not remediated; FDA's warning about cephalosporin contamination in products used by hospitals and health systems could affect supply availability for affected injectable drugs. The action does not change billing, coverage, or compliance program obligations for provider or payor organizations.
Informational only. Not legal, medical, financial, or other professional advice. Always consult a qualified professional familiar with your specific facts before relying on any item.
Related items
- FDA Warning Letters · October 14, 2026SCA Pharmaceuticals, LLCScore 50
- FDA Warning Letters · October 20, 2026Signature Formulations LLCScore 46
- FDA Warning Letters · October 7, 2026Amazon.com, Inc.Score 46
- FDA Warning Letters · October 20, 2026Rohto Pharmaceutical Co., Ltd.Score 43
- FDA Warning Letters · October 6, 2026Online Generic Medicine/www.onlinegenericmedicine.comScore 43
- FDA Warning Letters · October 20, 2026Olympus Medical Systems CorporationScore 40